Michael Makris/LinkedIn
Jan 19, 2026, 14:17
Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Another study showing the benefit of low-dose emicizumab (Hemlibra) in hemophilia A.
The patients were receiving half the approved dose of the drug.
Despite this, the mean Annual Bleed Rate (ABR) was 0.4, the median was 0.0 and 67% had zero bleeds.
If you saw these data, you would not know that the patients were only using half the approved dose.
Is it not time for a randomised study in Europe or North America of full vs half-dose emicizumab in severe hemophilia A?
Roche will clearly never do such a study, it will need to be done independently.”
Stay updated with Hemostasis Today.
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?
-
Sep 30, 2026, 13:03Amira Mohy: Diagnostic Flow Cytometry Panels for Hematological Malignancies
-
Sep 30, 2026, 12:52Paul Watton: Could Repetitive Head Impacts Leave a Molecular Memory?
-
Sep 30, 2026, 12:41The Journey to ISTH 2027 Starts in Vancouver